Data sourced from Joe, the private fund performance platform powered by Dakota. Learn More | Request Access
For deal sourcers, staying current on private company activity is critical to spotting active buyers, tracking market trends, and uncovering emerging investment opportunities ahead of competitors.
In July alone, we added more than 1,700 new private company transactions, bringing the total to over 27,900 searchable deals across sectors, industries, and transaction types in Joe powered by Dakota Marketplace.
Inside Joe, you’ll find the transactions tab that provides structured, filterable data on deal types, values, and dates, while our editorial team curates daily updates through the dakota transactions newsletter, helping you cut through the noise and focus on what matters most.
To ensure the most comprehensive coverage of private market activity, Dakota’s team monitors over 10,000 websites including company websites, newswires, and numerous third-party news providers to capture and verify transaction data as it happens.
Below are the top 10 health care transactions.
- Transaction Date: 7/6/2026
- Industry: Biotechnology
- Type: Acquisition / Merger
- Transaction Value: $10B
Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for $85/share in cash (~$10.0B equity value, ~$8.8B net of cash), gaining PALSONIFY, the first once-daily oral therapy for acromegaly, and pipeline candidate atumelnant, a Phase 3 CAH treatment. The deal, expected to close Q3 2026, is backed by $4.5B in bridge financing from Bank of America and Morgan Stanley.
- Transaction Date: 7/16/2026
- Industry: Biotechnology
- Type: Acquisition / Merger
- Transaction Value: $4.1B
Angelini Pharma has completed its acquisition of Catalyst Pharmaceuticals for $31.50/share in cash, valuing the deal at roughly $4.1 billion, expanding Angelini's brain health and rare disease portfolio into the U.S. market. The deal is backed by €1 billion equity investments each from Blackstone and CDP Equity, plus debt financing from a 14-bank syndicate led by BNP Paribas.
- Transaction Date: 7/16/2026
- Industry: Biotechnology
- Type: Acquisition / Merger
- Transaction Value: $3.8B
Eli Lilly will acquire AtaiBeckley for $6.75/share upfront cash (~$2.8B equity value) plus up to $2.50/share in contingent milestone payments (~$1.0B more), gaining lead asset BPL-003—a Breakthrough Therapy-designated treatment for treatment-resistant depression now in Phase 3. The deal, expected to close Q3 2026, expands Lilly's neuroscience pipeline into rapid-acting neuroplastogens targeting synaptic connectivity rather than traditional neurotransmitter pathways.
- Transaction Date: 7/13/2026
- Industry: Pharmaceuticals
- Type: Acquisition / Merger
- Transaction Value: $2.65B
Servier has completed its acquisition of Edgewise Therapeutics' muscular dystrophy business, including lead asset sevasemten, for up to $2.65 billion ($1.55 billion upfront plus $1.1 billion in milestones). The deal lets Edgewise sharpen its focus on its cardiovascular pipeline (EDG-7500, EDG-15400, EDG-003) while giving Servier a late-stage neuromuscular disorder program supporting its Becker and Duchenne muscular dystrophy ambitions.
- Transaction Date: 7/6/2026
- Industry: Pharmaceuticals
- Type: Acquisition / Merger
- Transaction Value: $2.0B
Incyte has completed its acquisition of Vega Therapeutics, a Star Therapeutics subsidiary, for $1.25 billion upfront plus up to $750 million in sales milestones (up to $2.0 billion total), gaining VGA039—a Phase 3, Breakthrough Therapy-designated antibody for von Willebrand disease. The deal expands Incyte's hematology portfolio into bleeding disorders, with VGA039 positioned as a potential first subcutaneous prophylactic alternative to frequent IV infusions.
Want to track health care deal activity like this as it happens? Explore the full transactions tab in Joe for real-time, filterable data on every deal in this sector.
- Transaction Date: 7/23/2026
- Industry: Health Care Technology
- Type: Buyout / Private Equity
- Transaction Value: $2.00B
Dassault Systèmes has agreed to acquire ArisGlobal, a life sciences regulatory and safety software provider, from Nordic Capital in a deal valued up to $2 billion, marking a full exit for Nordic Capital after its 2019 investment. ArisGlobal, whose LifeSphere and AI-driven NavaX platforms serve over 200 life sciences companies and generate roughly $175 million in expected 2026 revenue, will combine with Dassault's research, clinical development, and manufacturing capabilities, with closing expected in H2 2026.
- Transaction Date: 7/20/2026
- Industry: Biotechnology
- Type: Acquisition / Merger
- Transaction Value: $1.9B
Tempus AI will acquire Personalis for $16.25/share (~$1.5 billion enterprise value, net of Tempus' existing stake) in a stock-and-cash deal, deepening a partnership formed in 2023 around Personalis' NeXT Personal MRD test for cancer monitoring. The deal integrates Personalis' ultrasensitive minimal residual disease technology into Tempus' AI-driven precision oncology platform, targeting a $20 billion MRD market, with closing expected late 2026 or early 2027.
- Transaction Date: 7/8/2026
- Industry: Health Care Providers & Services
- Type: Real Assets
- Transaction Value: $1.7B
Blue Owl Capital, together with Moor Park Capital Partners, has completed the acquisition of a 12-hospital portfolio operated by Spire Healthcare, the UK's leading private hospital operator, expanding Blue Owl's European Net Lease real estate strategy. The deal, financed via a secured term loan led by Standard Chartered, Natixis, and Crédit Agricole CIB, adds long-term leased healthcare real estate to Blue Owl's $315 billion Real Assets platform.
- Transaction Date: 7/6/2026
- Industry: Biotechnology
- Type: Acquisition / Merger
- Transaction Value: $1.5B
Novartis will acquire privately held Myricx Bio for $1.1 billion upfront plus up to $400 million in milestones, gaining a novel NMT-inhibitor payload platform for antibody-drug conjugates designed to overcome resistance seen with current ADC payloads like TOPO-1 inhibitors. The deal adds two lead ADC assets targeting B7-H3 and HER2 to Novartis' oncology pipeline, with closing expected in H2 2026.
- Transaction Date: 7/1/2026
- Industry: Biotechnology
- Type: Growth Equity
- Transaction Value: $1.00B
BridgeBio Pharma has secured up to $1 billion in convertible preferred equity from Sixth Street ($800 million, lead) and HealthCare Royalty/KKR ($133.9 million), carrying a 7% dividend and a conversion price set at more than a 100% premium to BridgeBio's 30-day average share price. The financing gives BridgeBio permanent, non-maturing capital to support the anticipated approval and launch of three new therapies for genetic conditions.
Transactions in Joe, Powered by Dakota
At Dakota, we understand how important it is to stay current on deal activity as it happens. That’s why our editorial team continuously monitors the news for real-time updates on platform investments, add-ons, divestitures, and more to deliver daily highlights straight to your inbox through our transactions newsletter.
Inside Joe, the transactions tab provides structured, filterable data with deal dates, types, sectors, and financials, allowing you to build a customized feed that aligns with your focus areas.
Whether you're evaluating a new investment opportunity or tracking trends within a target sector, Joe helps you cut through the noise and focus on what matters most.
For more information on these transactions and a deeper dive into their industries and sub-industries, request access to Joe.
